Payment overview · 2025
General Payments
$1,579.07
87 reported records · 18 companies
Healthcare provider profile · identity verified
James Richard Gewin, MD
Allopathic & Osteopathic Physicians|Family Medicine · BIRMINGHAM, AL · NPI 1497751127
Verified facts
What the public records show
CMS Open Payments records show James Richard Gewin, MD received $1,579.07 in general payments during 2025 across 87 reported records.
Axsome Therapeutics, Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $299.89 | 19.0% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $263.29 | 16.7% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $194.40 | 12.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $147.29 | 9.3% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.43 | 7.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.12 | 5.2% | 5 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $81.35 | 5.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.04 | 4.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.57 | 3.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $52.22 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.81 | 3.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.16 | 3.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $30.83 | 1.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.49 | 1.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.32 | 1.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.99 | 1.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.96 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.91 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,579.07 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $192.99 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $182.42 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $155.99 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $147.29 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.78 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.03 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $106.90 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $102.67 | 6 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $81.35 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $79.75 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $78.30 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.57 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.49 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $52.22 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.81 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.39 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.16 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $11.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $11.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $11.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 129 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 522 | 167 |
| Losartan Potassium | Losartan Potassium | 416 | 127 |
| Gabapentin | Gabapentin | 398 | 68 |
| Clonazepam | Clonazepam | 397 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 113 |
| Alprazolam | Alprazolam | 332 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 298 | 43 |
| Tramadol Hcl | Tramadol Hcl | 249 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 82 |
| Trazodone Hcl | Trazodone Hcl | 200 | 61 |
| Omeprazole | Omeprazole | 195 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 36 |
| Lisinopril | Lisinopril | 172 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 57 |
| Atenolol | Atenolol | 147 | 44 |
| Metformin Hcl | Metformin Hcl | 145 | 43 |
| Eliquis | Apixaban | 129 | 29 |
| Furosemide | Furosemide | 129 | 43 |
| Montelukast Sodium | Montelukast Sodium | 125 | 43 |
| Promethazine Hcl | Promethazine Hcl | 122 | 23 |
| Famotidine | Famotidine | 121 | 38 |
| Simvastatin | Simvastatin | 113 | 33 |
| Lorazepam | Lorazepam | 109 | 19 |
| Finasteride | Finasteride | 107 | 28 |
| Bupropion Xl | Bupropion Hcl | 105 | 41 |
| Allopurinol | Allopurinol | 102 | 27 |
| Methocarbamol | Methocarbamol | 102 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 99 | 33 |
| Sertraline Hcl | Sertraline Hcl | 96 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 31 |
| Prednisone | Prednisone | 91 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 29 |
| Fluconazole | Fluconazole | 88 | 37 |
| Azithromycin | Azithromycin | 84 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 34 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 78 | 11 |
| Potassium Chloride | Potassium Chloride | 77 | 26 |
| Celecoxib | Celecoxib | 76 | 25 |
| Meloxicam | Meloxicam | 73 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 25 |
| Pregabalin | Pregabalin | 68 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 19 |
| Glimepiride | Glimepiride | 67 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 21 |
| Carvedilol | Carvedilol | 63 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 19 |
| Estradiol | Estradiol | 60 | 22 |
| Jardiance | Empagliflozin | 57 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 13 |
| Valacyclovir | Valacyclovir Hcl | 55 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Mirtazapine | Mirtazapine | 50 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 17 |
| Temazepam | Temazepam | 48 | suppressed |
| Cefdinir | Cefdinir | 47 | 41 |
| Memantine Hcl | Memantine Hcl | 47 | 14 |
| Azelastine Hcl | Azelastine Hcl | 44 | 16 |
| Ozempic | Semaglutide | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 27 |
| Diazepam | Diazepam | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 11 |
| Ondansetron Odt | Ondansetron | 36 | 15 |
| Nystatin | Nystatin | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Donepezil Hcl | Donepezil Hcl | 33 | 13 |
| Baclofen | Baclofen | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 12 |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Valsartan | Valsartan | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Primidone | Primidone | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Budesonide Dr | Budesonide | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 13 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,579.07 · 87 records | Axsome Therapeutics, Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, General - Pain Management, JATENZO, Jornay PM, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error